EE50 A Cost-Consequence Model of Using the 21-Gene Breast Recurrence Score Assay to Identify Patients With Early-Stage Node-Positive Breast Cancer Who Benefit From Adjuvant Chemotherapy in the Netherlands
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.303
https://www.valueinhealthjournal.com/article/S1098-3015(22)02507-4/fulltext
Title :
EE50 A Cost-Consequence Model of Using the 21-Gene Breast Recurrence Score Assay to Identify Patients With Early-Stage Node-Positive Breast Cancer Who Benefit From Adjuvant Chemotherapy in the Netherlands
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02507-4&doi=10.1016/j.jval.2022.09.303
First page :
Section Title :
Open access? :
No
Section Order :
12114